A Multi-Center, Randomized, Double-Blind, Parallel-Group, Multiple-Dose Study Assessing the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of GK1-399 in Patients With Type 2 Diabetes Mellitus
Phase of Trial: Phase II
Latest Information Update: 12 May 2016
At a glance
- Drugs TTP 399 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Forest Laboratories; TransTech Pharma
- 12 May 2016 Data presented at the Keystone Symposia on New Therapeutics for Diabetes and Obesity 2016, according to a vTv Therapeutics media release.
- 14 Aug 2013 Results published in the Media Release.
- 07 Sep 2012 Actual end date (Sep 2012) added as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History